The Wearables Are Growing Up: Rings Get Records, Straps Get Strategic, Watches Get Cleared
For years, the wearables industry has thrived on calculated ambiguity — close enough to medicine to feel meaningful, far enough away to dodge most of the regulatory machinery. In April, that gap narrowed. ŌURA, WHOOP, and Samsung each made moves that point in the same broad direction: clinical-grade health platforms, with women's health, biomarker integration, and institutional credibility as the new areas of focus.
ŌURA went inward. The company acquired Galen AI, a Stanford-founded startup that aggregates fragmented data, such as lab results, medications, and visit histories, to sit underneath the Ring's continuous biometric feed. Days earlier, ŌURA partnered with Mira to fold lab-grade hormone measurements into the same app, building out cycle, fertility, and menopause tracking with actual biomarker data rather than calendar estimates. The unifying thesis is straightforward enough: biometric data without the richness of clinical context is trivial; with context, it starts to resemble a meaningful longitudinal health record, one you can hang your evidentiary hat on.
WHOOP took a different route to the same destination. The company closed a $575M Series G at a $10.1B valuation (yikes - so massive it would warrant its own piece on how it came to be), nearly tripling its 2021 mark. The athlete cap table (see Ronaldo, LeBron, McIlroy) got most of the headlines, but the meaningful names for us in healthcare are Abbott and Mayo Clinic — Abbott in particular signalling, in a structural mirror of Dexcom's earlier investment in ŌURA, that wearables and continuous biosensing are heading for the same clinical pipeline. WHOOP also secured a contract with MIT Lincoln Laboratory to support a U.S. Navy crew-readiness program, the kind of institutional validation that does tip the needle further into the space of clinical legitimacy. Worth noting: WHOOP's Blood Pressure Insights (BPI) feature remains in an unresolved scrap with the U.S. Food and Drug Administration (FDA) over whether it qualifies as a medical device — even after January's General Wellness guidance largely tilted in WHOOP's favour. Clinical legitimacy and regulatory scrutiny tend to be the same thing dressed differently.
Samsung, meanwhile, took a third route: cleared, cautious, consumer. The Galaxy Watch8's blood-pressure feature launched in the U.S., using pulse-wave analysis with a mandatory cuff calibration every 28 days — a regulatory hedge that lets the watch offer cuffless trend data without claiming to diagnose anything. Apple cleared this lane months ago. WHOOP argued the toss.
UnitedHealthcare's Rural Charm Offensive: Generous, Strategic, and Conveniently Timed
On April 20, UnitedHealthcare (UHC) announced it will exempt approximately 1,500 rural hospitals — including every Critical Access Hospital (CAH) in the country — from most prior authorisation (PA) requirements by fall 2026, accelerate payments to those facilities by up to 50%, and launch hub-and-spoke partnerships starting with maternal care, diabetes, and post-surgical care.
For rural hospitals, this is genuinely meaningful. The Chartis Center for Rural Health found that nearly half of U.S. rural hospitals are operating in the red. Faster cash and fewer faxes can be the difference between solvent and not.
The harder question isn't whether the announcement helps. It's why this announcement, and why now.
“Timely” is the word. The Department of Justice (DOJ) is currently running civil and criminal probes into UnitedHealth's Medicare Advantage (MA) billing, which has since been extended to OptumRx and physician reimbursement. In January, the same week UHC launched its Rural Payment Acceleration Pilot, Senate Judiciary Committee chair Chuck Grassley released a 50,000-record review concluding that UnitedHealth has been "aggressively gaming" MA to inflate federal reimbursements. The company's stock has shed roughly half its value in the past year. Stephen Hemsley has returned as CEO since. Goodwill, in this environment, is the cheapest insurance policy money can buy.
Now look at what's actually being given up. Rural hospitals, particularly the country's roughly 1,381 Critical Access Hospitals, refer most high-acuity specialty care (chemotherapy, advanced imaging, complex surgery) out to academic medical centres. The PAs that hurt most (cancer regimens, MRIs, specialty drugs) happen there, after the referral. UHC is easing the PA burden for the venue that handles the lower-acuity end of the care continuum. That genuinely helps rural CFOs and improves friction for local care. The high-stakes prior auths, where delays translate into worse outcomes, sit untouched at the next stop in the referral chain.
The hub-and-spoke piece is where the strategic logic surfaces. UHC's parent owns Optum, which operates one of the largest physician networks in the United States. "Connecting community-based access points with regional clinical expertise" is referral architecture. Maternal, diabetes, and post-surgical care — the named focus areas — are precisely the high-frequency, high-cost channels where shaping referral patterns delivers serious downstream value.
Good for rural hospitals, modestly. Good for healthcare? Next question please.
DEXA Joins the Longevity Stack: Gold-Standard Tech, Murkier Use Case
In April, Hone Health, a longevity-focused telehealth provider, announced a partnership with BodySpec to integrate clinical-grade DEXA body composition scans into its app. Patients can purchase a scan, view the results in the platform, and have a Hone clinician interpret them alongside hormone and metabolic data. It's the latest confirmation that DEXA, long a quiet workhorse of clinical bone screening, has firmly entered the consumer longevity stack.
A bit of background. DEXA, or dual-energy X-ray absorptiometry, was developed in the 1980s, cleared by the U.S. Food and Drug Administration (FDA) in 1988, and codified into reimbursement standard practice by the 1998 Bone Mass Measurements Act. The mechanism is straightforward: two X-ray beams at different energy levels, with differential absorption mapped across bone, fat, and lean tissue. Whole-body scans take 10–30 minutes at roughly 1 microsievert (μSv) of radiation — about a hundredth of a chest X-ray.
The accuracy is genuinely best-in-class. Peer-reviewed studies show 1–2% precision for whole-body composition, comfortably better than bioelectrical impedance scales (3–5% error) or the InBody machines in your local gym (6–15% off). DEXA is the yardstick against which other body-composition methods are validated.
The clinical use case is similarly settled. For decades, DEXA has been the diagnostic of record for osteoporosis screening — typically ordered for postmenopausal women, men over 50, or patients on bone-loss-inducing medication. The body composition segment is expanding faster, at 6.15% CAGR — driven by athletes, biohackers, and the longevity crowd, not new clinical indications.
DEXA's accuracy is real. The actionability of that accuracy for the average longevity customer is much less so - which seems to be a bit of a running thread in that space. A 35-year-old getting a scan every six months learns precise body-fat distribution numbers, but those numbers rarely change clinical management. Most of what consumers do with DEXA results like adjust training, tweak protein intake, is achievable with cheaper proxies and an honest bathroom mirror.
Hone's specific pitch is the most defensible angle in the category: traditional DEXA scans are ordered after age 65, often too late to meaningfully restore bone density. Catching declining bone mineral density or sarcopenia at 45, when behaviour change can still bend the curve, is genuine clinical territory. That use case earns its keep, and is symptomatic of a very important push toward preventative care. The 35-year-old optimising vanity metrics? Less so.
Gold-standard tech doesn't automatically produce gold-standard outcomes. It just produces gold-standard data. What the user does with the data - that’s where the value of a product is.
